Replies to post #125025 on Biotech Values

[EYEBUYSTOX]

VRX is looking for dermatology products it can sell. We can talk about acne scars when there are clinical data to show that laViv is safe and effective in that indication, which will be several years from now, if ever.

The timing of an FDA approval for acne scarring will be clearer after FCSC meets with the FDA later this year and I'm confident that their Regulatory VP, Jeanne Novak (served as a FDA Senior scientist, credentialed Inspector and expert advisor to FDA Center Directors) will successfully negotiate the most efficient pathway possible. I highly doubt it will be several years (considering the trials for naso-labial folds were only 6 months) and an approval is more likely now that LaViv has been proven effective in other indications and safety is a nominal concern, IMO.

You must admit that most small biotech companies are traded based in part on valuations that include the potential of their pipelines. Considering FCSC has more than $20 million in cash and the pipeline for acne scarring could tap a market of millions of acne scar sufferers with few other viable options, the company's current valuation of approx. $70 million is low.

This board is called Biotech Values, so I thought I'd share my belief that FCSC is one of them and encourage any followers here to do their own "Dew Diligence" on FCSC.